3 completed. 2 Phase 1, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Early Phase 1 | 1 | Completed 1 |
Follow Nanexa AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D NEX-22A, a prolonged release formulation of liraglutide - Type 2 Diabetes | Phase 1 | Completed | Nanexa AB | 12 | 2024-05-27 | 2025-09-23 |
| To Assess Safety, Tolerability and PK of NEX-20A, a Subcutaneous Prolonged-release Injection to Healthy Subjects NEX-20A - Multiple Myeloma | Early Phase 1 | Completed | Nanexa AB | 9 | 2022-11-28 | 2023-10-31 |
| Pharmacokinetics, Tolerability and Safety of NEX-18a NEX-18a injection, Azacitidine Injection - Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) | Phase 1 | Completed | Nanexa AB | 2 | 2021-04-27 | 2023-10-17 |
Diabetes Mellitus, Type 2 (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1)
Azacitidine (1)
Sweden (2) · Germany (1)
Grit Andersen, MD (1) · Hjalmar Flygt (1)